Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113


XRCC1 Polymorphism Associated With Late Toxicity After Radiation Therapy in Breast Cancer Patients.

Seibold P, Behrens S, Schmezer P, Helmbold I, Barnett G, Coles C, Yarnold J, Talbot CJ, Imai T, Azria D, Koch CA, Dunning AM, Burnet N, Bliss JM, Symonds RP, Rattay T, Suga T, Kerns SL, Bourgier C, Vallis KA, Sautter-Bihl ML, Claßen J, Debus J, Schnabel T, Rosenstein BS, Wenz F, West CM, Popanda O, Chang-Claude J.

Int J Radiat Oncol Biol Phys. 2015 Apr 11. pii: S0360-3016(15)00409-5. doi: 10.1016/j.ijrobp.2015.04.011. [Epub ahead of print]


Radiogenomics: the search for genetic predictors of radiotherapy response.

Kerns SL, West CM, Andreassen CN, Barnett GC, Bentzen SM, Burnet NG, Dekker A, De Ruysscher D, Dunning A, Parliament M, Talbot C, Vega A, Rosenstein BS.

Future Oncol. 2014 Dec;10(15):2391-406. doi: 10.2217/fon.14.173.


A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1.

Fachal L, Gómez-Caamaño A, Barnett GC, Peleteiro P, Carballo AM, Calvo-Crespo P, Kerns SL, Sánchez-García M, Lobato-Busto R, Dorling L, Elliott RM, Dearnaley DP, Sydes MR, Hall E, Burnet NG, Carracedo Á, Rosenstein BS, West CM, Dunning AM, Vega A.

Nat Genet. 2014 Aug;46(8):891-4. doi: 10.1038/ng.3020. Epub 2014 Jun 29.


Radiogenomics: radiobiology enters the era of big data and team science.

Rosenstein BS, West CM, Bentzen SM, Alsner J, Andreassen CN, Azria D, Barnett GC, Baumann M, Burnet N, Chang-Claude J, Chuang EY, Coles CE, Dekker A, De Ruyck K, De Ruysscher D, Drumea K, Dunning AM, Easton D, Eeles R, Fachal L, Gutiérrez-Enríquez S, Haustermans K, Henríquez-Hernández LA, Imai T, Jones GD, Kerns SL, Liao Z, Onel K, Ostrer H, Parliament M, Pharoah PD, Rebbeck TR, Talbot CJ, Thierens H, Vega A, Witte JS, Wong P, Zenhausern F; Radiogenomics Consortium.

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):709-13. doi: 10.1016/j.ijrobp.2014.03.009. No abstract available.


A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity.

Barnett GC, Thompson D, Fachal L, Kerns S, Talbot C, Elliott RM, Dorling L, Coles CE, Dearnaley DP, Rosenstein BS, Vega A, Symonds P, Yarnold J, Baynes C, Michailidou K, Dennis J, Tyrer JP, Wilkinson JS, Gómez-Caamaño A, Tanteles GA, Platte R, Mayes R, Conroy D, Maranian M, Luccarini C, Gulliford SL, Sydes MR, Hall E, Haviland J, Misra V, Titley J, Bentzen SM, Pharoah PD, Burnet NG, Dunning AM, West CM.

Radiother Oncol. 2014 May;111(2):178-85. doi: 10.1016/j.radonc.2014.02.012. Epub 2014 Apr 28.


Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy.

Kerns SL, Ostrer H, Rosenstein BS.

Cancer Discov. 2014 Feb;4(2):155-65. doi: 10.1158/2159-8290.CD-13-0197. Epub 2014 Jan 17. Review.


STROGAR - STrengthening the Reporting Of Genetic Association studies in Radiogenomics.

Kerns SL, de Ruysscher D, Andreassen CN, Azria D, Barnett GC, Chang-Claude J, Davidson S, Deasy JO, Dunning AM, Ostrer H, Rosenstein BS, West CM, Bentzen SM.

Radiother Oncol. 2014 Jan;110(1):182-8. doi: 10.1016/j.radonc.2013.07.011. Epub 2013 Aug 27.


Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer.

Kerns SL, Stock RG, Stone NN, Blacksburg SR, Rath L, Vega A, Fachal L, Gómez-Caamaño A, De Ruysscher D, Lammering G, Parliament M, Blackshaw M, Sia M, Cesaretti J, Terk M, Hixson R, Rosenstein BS, Ostrer H.

Radiother Oncol. 2013 Jun;107(3):372-6. doi: 10.1016/j.radonc.2013.05.001. Epub 2013 May 26.


A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms after radiotherapy for prostate cancer.

Kerns SL, Stone NN, Stock RG, Rath L, Ostrer H, Rosenstein BS.

J Urol. 2013 Jul;190(1):102-8. doi: 10.1016/j.juro.2013.01.096. Epub 2013 Feb 1.


Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity.

Barnett GC, Elliott RM, Alsner J, Andreassen CN, Abdelhay O, Burnet NG, Chang-Claude J, Coles CE, Gutiérrez-Enríquez S, Fuentes-Raspall MJ, Alonso-Muñoz MC, Kerns S, Raabe A, Symonds RP, Seibold P, Talbot CJ, Wenz F, Wilkinson J, Yarnold J, Dunning AM, Rosenstein BS, West CM, Bentzen SM.

Radiother Oncol. 2012 Dec;105(3):289-95. doi: 10.1016/j.radonc.2012.10.017. Epub 2012 Nov 28.


A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of erectile dysfunction following radiation therapy for prostate cancer.

Kerns SL, Stock R, Stone N, Buckstein M, Shao Y, Campbell C, Rath L, De Ruysscher D, Lammering G, Hixson R, Cesaretti J, Terk M, Ostrer H, Rosenstein BS.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e21-8. doi: 10.1016/j.ijrobp.2012.08.003. Epub 2012 Sep 26.


γ-H2AX kinetics as a novel approach to high content screening for small molecule radiosensitizers.

Fu S, Yang Y, Das TK, Yen Y, Zhou BS, Zhou MM, Ohlmeyer M, Ko EC, Cagan R, Rosenstein BS, Chen SH, Kao J.

PLoS One. 2012;7(6):e38465. doi: 10.1371/journal.pone.0038465. Epub 2012 Jun 29. Erratum in: PLoS One. 2012;7(9). doi:10.1371/annotation/0d7595f1-c719-4ed9-bef0-8308f4cac7e3. Tirtha, Das [corrected to Das, Tirtha K].


Genome-wide association studies and prediction of normal tissue toxicity.

West CM, Dunning AM, Rosenstein BS.

Semin Radiat Oncol. 2012 Apr;22(2):91-9. doi: 10.1016/j.semradonc.2011.12.007. Review. No abstract available.


Predicting toxicity from radiation therapy--it's genetic, right?

Kelsey CR, Rosenstein BS, Marks LB.

Cancer. 2012 Jul 15;118(14):3450-4. doi: 10.1002/cncr.26670. Epub 2011 Dec 5. No abstract available.


Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study.

Teraoka SN, Bernstein JL, Reiner AS, Haile RW, Bernstein L, Lynch CF, Malone KE, Stovall M, Capanu M, Liang X, Smith SA, Mychaleckyj J, Hou X, Mellemkjaer L, Boice JD Jr, Siniard A, Duggan D, Thomas DC; WECARE Study Collaborative Group, Concannon P.

Breast Cancer Res. 2011;13(6):R114. doi: 10.1186/bcr3057. Epub 2011 Nov 17.


Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 as a Novel Approach to Enhance Radiotherapy.

Fu S, Rivera M, Ko EC, Sikora AG, Chen CT, Vu HL, Cannan D, Eisenstein S, Rosenstein BS, Aguirre-Ghiso J, Chen SH, Kao J.

J Cell Sci Ther. 2011 Oct 13;1(2). pii: S1-002.


Radiobiological rationale and clinical implications of hypofractionated radiation therapy.

Ko EC, Forsythe K, Buckstein M, Kao J, Rosenstein BS.

Cancer Radiother. 2011 Jun;15(3):221-9. doi: 10.1016/j.canrad.2010.12.007. Epub 2011 Apr 21. Review.


Introduction to radiation safety and monitoring.

Cuaron JJ, Hirsch AE, Medich DC, Hirsch JA, Rosenstein BS.

J Am Coll Radiol. 2011 Apr;8(4):259-64. doi: 10.1016/j.jacr.2010.08.020. Review.


Identification of SNPs associated with susceptibility for development of adverse reactions to radiotherapy.

Rosenstein BS.

Pharmacogenomics. 2011 Feb;12(2):267-75. doi: 10.2217/pgs.10.186.


Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy.

Stone NN, Stone MM, Rosenstein BS, Unger P, Stock RG.

J Urol. 2011 Feb;185(2):495-500. doi: 10.1016/j.juro.2010.09.099. Epub 2010 Dec 17.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk